As the world ushered in the New Year, there was good news on Day One. Every Indian was waiting for this news for the last nine months. The subject expert committee of the Drugs Controller General of India on Friday recommended Emergency Use Authorisation(EUA) for the Oxford-Zeneca Covishield vaccine manufactured at Serum Institute of India, Pune. This is a conditional approval that entails that every recipient of the vaccine shall be given a factsheet about the vaccine prior to inoculation. The company has been asked to submit reports on adverse events every fortnight. Two full doses of Covishield will be given to every recipient within a gap of 4-6 weeks. The DCGI is going to give marketing approval within a day or two.